Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.06.2022 | Case report

Ipilimumab

Grave's disease: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Manzoor S. Abstract #1004335: An Unusual Case of Rapidly Evolving Thyroidal Dysfunction from New Onset Antibody Negative Graves' Disease to Central Hypothyroidism Within Few Weeks of Starting Ipilimumab (Immune Check Point Inhibitor) Therapy. Endocrine Practice 27 (Suppl.): S182, No. 6, Jun 2021. Available from: URL: http://doi.org/10.1016/j.eprac.2021.04.855 [abstract] Manzoor S. Abstract #1004335: An Unusual Case of Rapidly Evolving Thyroidal Dysfunction from New Onset Antibody Negative Graves' Disease to Central Hypothyroidism Within Few Weeks of Starting Ipilimumab (Immune Check Point Inhibitor) Therapy. Endocrine Practice 27 (Suppl.): S182, No. 6, Jun 2021. Available from: URL: http://​doi.​org/​10.​1016/​j.​eprac.​2021.​04.​855 [abstract]
Metadaten
Titel
Ipilimumab
Grave's disease: case report
Publikationsdatum
01.06.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-16583-3

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Warfarin

Case report

Thiamazole